» Articles » PMID: 28489290

Obesity: a Chronic Relapsing Progressive Disease Process. A Position Statement of the World Obesity Federation

Overview
Journal Obes Rev
Specialty Endocrinology
Date 2017 May 11
PMID 28489290
Citations 480
Authors
Affiliations
Soon will be listed here.
Abstract

This paper considers the argument for obesity as a chronic relapsing disease process. Obesity is viewed from an epidemiological model, with an agent affecting the host and producing disease. Food is the primary agent, particularly foods that are high in energy density such as fat, or in sugar-sweetened beverages. An abundance of food, low physical activity and several other environmental factors interact with the genetic susceptibility of the host to produce positive energy balance. The majority of this excess energy is stored as fat in enlarged, and often more numerous fat cells, but some lipid may infiltrate other organs such as the liver (ectopic fat). The enlarged fat cells and ectopic fat produce and secrete a variety of metabolic, hormonal and inflammatory products that produce damage in organs such as the arteries, heart, liver, muscle and pancreas. The magnitude of the obesity and its adverse effects in individuals may relate to the virulence or toxicity of the environment and its interaction with the host. Thus, obesity fits the epidemiological model of a disease process except that the toxic or pathological agent is food rather than a microbe. Reversing obesity will prevent most of its detrimental effects.

Citing Articles

The Effect of Adding a Smartphone-Based Platform to the Metabolic Bariatric Surgery Nutritional Preparation Process: A Randomized Controlled Trial.

Kessler Y, Boaz M, Mardy-Tilbor L, Raziel A, Sakran N, Goitein D Obes Surg. 2025; .

PMID: 40072742 DOI: 10.1007/s11695-025-07732-9.


Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.

Yang S, Xin S, Ju R, Zang P PLoS One. 2025; 20(2):e0314787.

PMID: 40014613 PMC: 11867386. DOI: 10.1371/journal.pone.0314787.


Flavonoids as Potential Modulators of Pancreatic Lipase Catalytic Activity.

Rocha S, Proenca C, Araujo A, Freitas M, Rufino I, Aniceto N Pharmaceutics. 2025; 17(2).

PMID: 40006530 PMC: 11859905. DOI: 10.3390/pharmaceutics17020163.


Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.

Kushner R, Ryan D, Deanfield J, Kokkinos A, Cercato C, Wilding J Obesity (Silver Spring). 2025; 33(3):452-462.

PMID: 39948761 PMC: 11897845. DOI: 10.1002/oby.24222.


Modulatory Effects of Multi-species/Multi-strain Synbiotic and L-carnitine Concomitant Supplementation on Atherogenic-Indices, Body Composition, Visceral Obesity, and Appetite in Metabolically Healthy Women with Obesity: A Double-Blind Randomized....

Fallah F, Mahdavi R Probiotics Antimicrob Proteins. 2025; .

PMID: 39921845 DOI: 10.1007/s12602-025-10460-2.